Medical News Interviews
The Audio Journal of Oncology
Reporting from the 2016 Congress of the European Society of Medical Oncology
COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab extended overall survival when compared head-to-head with docetaxel among patients with previously-treated non-small cell …
COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced non-squamous non-small-cell lung cancer (NSCLC) and good performance status significantly improved objective response rate (ORR) and progression-free …
NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblastic leukemia and otherwise had very short life expectancies. Stephan A Grupp, …
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin
In this edition Peter Goodwin and Sara Freeman report from:
European Breast Cancer Conference, Berlin, April 15-19, 2008;
Chemotherapy …
  Daniel Petrylak |   Oliver Sartor |   Mark Socinski |   Kanti Rai |   Edward Ambinder |
REFERENCE: Chemotherapy Foundation Symposium XXIV 8-11 November 2006
DANIEL PETRYLAK, Columbia Presbyterian Medical Center, New York
COMMENT: EDWARD AMBINDER, Mount
  George Canellos |   Sandra Strauss |   Nancy Baxter |
REFERENCES: J Clin Oncol 34:3904, 3927,
